Plasmodium vivax liver stage

The Plasmodium vivax liver stage encompasses both replicative (schizont) and dormant (hypnozoite) forms of the parasite within hepatocytes. After sporozoite inoculation by a mosquito, the parasite invades hepatocytes and either immediately replicates (schizogony) or arrests as a hypnozoite, which can reactivate weeks to months later and cause clinical relapse[1][8]. Molecular features of this stage include a host-derived parasitophorous vacuole membrane (PVM), association with host aquaporin-3, and parasite-specific markers such as PvUIS4[1][5]. Relapse prevention requires drugs able to eradicate hypnozoites, such as primaquine or tafenoquine, though these present safety concerns for certain patient populations (e.g., those with G6PD deficiency)[7][8]. The underlying molecular mechanisms driving hypnozoite formation, persistence, and activation remain poorly understood, hampering the development of new therapeutics[7]. Research increasingly focuses on discovering molecular or host-pathogen interface targets within the liver stage to facilitate radical cure and prevent relapse.

Other names

P. vivax liver stagePlasmodium vivax hypnozoitePlasmodium vivax liver schizont

Primaquine/tafenoquine: oxidative stress induction and mitochondrial targeting in parasite (kills hypnozoites and active liver forms); Auphen: inhibition of host aquaporin-3 function, impairing parasite development within hepatocytes